Market Currents
Peregrine Pharmaceuticals (PPHM +41.7%) soars after it says interim results Phase II trials show...
-
Friday, September 7, 2012, 1:40 PM ETPeregrine Pharmaceuticals (PPHM +41.7%) soars after it says interim results Phase II trials show the combined use of its bavituximab drug candidate with chemotherapy drug docetaxel had a statistically significant improvement in the overall survival rate for lung cancer patients.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 8 comments:
Interesting to note that negative connotations were prevailing here at SA in form of articles while largely positive emotions were prevailing in the discussion of those articles. Coincidence? The articles were short-seller attacks. I am happy those short sellers now have a problem.
Your decision in this case will finally depend on what TruffelPig suggested above, i.e.., your next move would depend on "the price you bought the stock at. Your investment time frame. How much of your holdings is in it and whether you have the patience and nerves to hold long term?
Good luck.